Related Experiment Video
Updated: Feb 19, 2026

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
Assumption-Agnostic Deep Learning Framework for Holistic Clinical Trial Monitoring
Shaoming Yin1,2, Zheyang Wu3,4, Jianchang Lin5
1Takeda Pharmaceuticals, Cambridge, MA, USA. shaoming.yin@takeda.com.
None:
Recently developed machine learning-enabled approaches to quality tolerance limit (QTL) surveillance offer efficiencies over labour-intensive source data verification. However, their reliance on parametric assumptions, restriction to Poisson or Bernoulli data types, and treatment of subject visits as independent observations limit their performance in the heterogeneous, longitudinal settings typical of modern clinical trials. We propose an assumption-agnostic framework for anomaly detection that combines two key components: (1) a hierarchical, non-parametric, multi-dimensional deviation scoring scheme based on discrepancies between reconstructed and observed values, and (2) a long short-term memory autoencoder that learns the joint temporal distribution of all numeric variables. Together, these components enable continuous, centralized detection of anomalies-including QTL deviations-across all numeric data types and hierarchical levels (program, study, site, and participant). The framework ingests streaming data from electronic data capture systems, vendors, and embedded numeric representations of text, inferring a shared latent manifold that captures complex cross-domain relations and intra-subject dynamics without relying on predefined mappings or historical priors. As new data accrue, deviation score thresholds are continuously updated to maintain robust performance. We evaluated the framework using simulations modeled on real-world trial structures and anomaly patterns, along with a supporting case study. Results demonstrate substantial improvements in anomaly signal discrimination, significant reductions in unnecessary follow-up, and strong computational scalability. Anchored in the risk-based monitoring paradigm articulated in ICH E6(R3), the proposed framework provides sponsors with a practical toolset for earlier hazard detection, enhanced participant safety, and streamlined trial operations.
Related Concept Videos
Statistical Software for Data Analysis and Clinical Trials
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...